Moderna and Merck Announce Positive Phase 3 Trial Results for First mRNA Cancer Vaccine
Moderna (NASDAQ:MRNA) and Merck & Co. (NYSE:MRK) announced positive results from a landmark Phase 3 trial of an individualized neoantigen therapy using mRNA technology to treat melanoma patients who had their tumors surgically removed. The treatment, combined with Merck’s Keytruda immunotherapy drug, showed improved outcomes in delaying cancer recurrence and spread compared to Keytruda alone. The results mark the first successful Phase 3 trial for an mRNA-based personalized cancer vaccine, a significant milestone that could expand the use of this technology beyond infectious diseases. Moderna CEO Stéphane Bancel called it “a big moment for medicine,” while Merck’s Dr. Jane Healy highlighted how the treatment targets specific tumor mutations to enhance immune response. Both stocks responded positively: Moderna surged nearly 128%, and Merck rose over 1%. Analysts upgraded Moderna, noting its potential beyond infectious disease treatments. However, investors are cautioned that regulatory approval is still pending before commercialization can begin.
Topics: biotech stocks cancer treatment mRNA vaccine Phase 3 trial results